

上海医学科技奖项目公示

项目名称：复发卵巢癌手术技术体系的建立及应用

主要完成人：臧荣余，史庭燕，朱笕青，江榕，刘继红，陈可欣，张平，向礼兵，杨恭，冯艳玲

主要完成单位：复旦大学附属中山医院、中国科学院大学附属肿瘤医院（浙江省肿瘤医院）、中山大学肿瘤防治中心、复旦大学附属肿瘤医院

知识产权情况：（专利）无

发表论文著作情况：（10 篇）

- 1) Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021;22(4):439-49.
- 2) Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. *Ann Surg Oncol*. 2012;19(2):597-604.
- 3) Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Trope CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. *Br J Cancer*. 2011;105(7):890-6.
- 4) Shi T, Jiang R, Pu H, Yang H, Tu D, Dai Z, Cai Y, Zhang Y, Cheng X, Jia H, Tu R, Wang H, Tang J, Luan Y, Cai S, Zang R. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. *Br J Cancer*. 2019;121(5):425-8.
- 5) Shi T, Jiang R, Yu J, Yang H, Tu D, Dai Z, Shen Y, Zhang Y, Cheng X, Jia H, Tu R, Wang H, Tang J, Luan Y, Cai S, Zang R. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. *Br J Cancer*. 2018;119(1):12-8.
- 6) Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, Tang J, Zang R. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. *BMC Cancer*. 2015;15:583.

- 7) Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, Wang Q, Zang R. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. *Int J Cancer*. 2017;140(9):2051-9.
- 8) Chen K, Ma H, Li L, Zang R, Wang C, Song F, Shi T, Yu D, Yang M, Xue W, Dai J, Li S, Zheng H, Wu C, Zhang Y, Wu X, Li D, Xue F, Li H, Jiang Z, Liu J, Liu Y, Li P, Tan W, Han J, Jie J, Hao Q, Hu Z, Lin D, Ma D, Jia W, Shen H, Wei Q. Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. *Nat Commun*. 2014;5:4682.
- 9) Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu Y, Liu M, Meng J, Zang R, Zhang Z, Yang G. The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy. *Mol Cancer*. 2014;13:94.
- 10) Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, Zhang Y, Zhang P, Zhu T, Aoki D, Yu A, Chen X, Wang X, Zhu D, Zhang W, Jia H, Shi T, Gao W, Yin S, Feng Y, Xiang L, Okamoto A, Zang R. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. *J Gynecol Oncol*. 2020;31(5):e86.